Action plan for optimizing the design of clinical trials in chronic kidney disease
Vlado Perkovic, Jonathan C Craig, Worawon Chailimpamontree, Caroline S Fox, Guillermo Garcia-Garcia, Mohammed Benghanem Gharbi, Meg J Jardine, Ikechi G Okpechi, Neesh Pannu, Benedicte Stengel, Katherine R Tuttle, Katrin Uhlig, Andrew S Levey, Vlado Perkovic, Jonathan C Craig, Worawon Chailimpamontree, Caroline S Fox, Guillermo Garcia-Garcia, Mohammed Benghanem Gharbi, Meg J Jardine, Ikechi G Okpechi, Neesh Pannu, Benedicte Stengel, Katherine R Tuttle, Katrin Uhlig, Andrew S Levey
Abstract
High-quality clinical trials are the cornerstone of evidence-based prevention and treatment of a disease, but nephrology has a strikingly weak base of such trials. Building the evidence base to improve outcomes for people with a kidney disease, therefore, requires both greater quantity and quality of clinical trials. To address these issues, we propose that we aim to enroll 30% of people with chronic kidney disease in trials by 2030. Goal 1: Strongly encourage and promote the conduct of clinical trials in people with chronic kidney disease to increase the number of clinical trials conducted. Goal 2: Optimize the design of clinical trials in people with chronic kidney disease. Goal 3: Increase the capacity for conducting clinical trials in people with chronic kidney disease.
Keywords: chronic kidney disease; clinical trial; clinical trial design; clinical trial endpoints.
Figures
Source: PubMed